Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Abstract

Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.

1 . A method of treating or managing sexual dysfunction in a mammal in need of treatment comprising administering on an as-needed basis to the mammal an amount of a rapid-onset selective serotonin reuptake inhibitor that is therapeutically effective in the absence of a priming dose.  
   
   
       2 . The method of  claim 1 , wherein the mammal is a human male.  
   
   
       3 . The method of  claim 1 , wherein the rapid-onset selective serotonin reuptake inhibitor is short acting.  
   
   
       4 . The method of  claim 1 , wherein the rapid-onset selective serotonin reuptake inhibitor is delivered in a rapid release formulation.  
   
   
       5 . The method of  claim 1 , comprising the additional step of administering a therapeutically effective amount of a second therapeutic agent for treating or managing a sexual dysfunction.  
   
   
       6 . A method of treating or managing sexual dysfunction in a mammal in need of such treatment comprising administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetine or a pharmaceutically acceptable salt thereof.  
   
   
       7 . The method of  claim 6 , wherein the mammal is a human male.  
   
   
       8 . The method of  claim 6 , comprising the additional step of administering a therapeutically effective amount of a second therapeutic agent for treating or managing sexual dysfunction.  
   
   
       9 . The method according to  claim 6 , wherein the therapeutically effective amount of dapoxetine is from about 0.001 mg to about 350 mg.  
   
   
       10 . The method of 6, wherein the therapeutically effective amount of dapoxetine or its pharmaceutically acceptable salt is from about 0.01 mg to about 200 mg.  
   
   
       11 . The method of 6, wherein the therapeutically effective amount of dapoxetine or its pharmaceutically acceptable salt is from about 0.1 mg to about 120 mg.  
   
   
       12 . The method of  claim 1   1 , wherein dapoxetine or its pharmaceutically acceptable salt is administered orally.  
   
   
       13 . The method of  claim 12 , wherein dapoxetine or its pharmaceutically acceptable salt is administered in an solid oral dosage form.  
   
   
       14 . The method of  claim 13 , wherein dapoxetine or its pharmaceutically acceptable salt is administered as a tablet or a capsule.  
   
   
       15 . The method of  claim 6 , wherein dapoxetine or its pharmaceutically acceptable salt is delivered as a rapid release formulation.